<乌鸦传媒>Novel Bispecific Antibody Active in Recurrent/Metastatic Head and Neck Cancer Responses in 37% of patients previously treated with anti-PD-1/L1 agents, platinum chemotherapy Apr 18, 2023
<乌鸦传媒>Responses to PD-1 Blockade Approach 90% in Rare Melanoma "One of the highest tumor response rates we've seen in any cancer," study discussant says Apr 17, 2023
<乌鸦传媒>Including Anti-PD-1 in First-Line Ups Survival in Biliary Tract Cancer Another option for difficult-to-treat disease Apr 17, 2023
<乌鸦传媒>'Potential' New Option for Operable NSCLC Adding perioperative durvalumab to neoadjuvant chemo improved pCR rates, event-free survival Apr 17, 2023
<乌鸦传媒>Adjuvant Combo May Change Practice in High-Risk Liver Cancer Atezolizumab-bevacizumab reduced the risk of recurrence by about 30% Apr 17, 2023
<乌鸦传媒>Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies Apr 17, 2023
<乌鸦传媒>Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
<乌鸦传媒>Anti-CD39 Combination Therapy Promising in Gastric/GEJ Cancer Responses in a majority of patients, evidence of durability with TTX-030, chemoimmunotherapy Apr 14, 2022
<乌鸦传媒>Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
<乌鸦传媒>Boosting Responses to Neoadjuvant Therapy in Resectable NSCLC Multi-drug platform study identifies promising durvalumab-based combinations Apr 12, 2022
<乌鸦传媒>Neoadjuvant Nivolumab a 'New Standard' in Lung Cancer "Another quantum leap in lung cancer therapy," expert says Apr 12, 2022
<乌鸦传媒>Genetic Score Shows Promise for Honing PSA Precision Fewer unnecessary biopsies projected with use of genetics-adjusted values Apr 12, 2022
<乌鸦传媒>PARP Inhibitor-Based Triplet Promising in Endometrial Cancer Olaparib/cyclophosphamide/metformin combo appears effective in older, heavily pretreated patients Apr 11, 2022
<乌鸦传媒>Longer-Term Sotorasib Data 'Encouraging' in KRAS-Mutated NSCLC Prolonged tumor response seen in 2-year analysis Apr 11, 2022
<乌鸦传媒>DCIS Recurrence Often Represents a New Primary Breast Cancer Almost a fifth of cases unrelated to primary DCIS, raising questions about current treatment Apr 11, 2022
<乌鸦传媒>Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trial Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
<乌鸦传媒>RET Fusion Inhibitor Active Beyond Lung, Thyroid Cancers Responses to selpercatinib in almost half of tumors outside approved indications May 21, 2021
<乌鸦传媒>New Anti-PD1 Drugs Boost Survival in Treated Lung Cancer Questions about generalizability of results with China-developed therapies Apr 14, 2021
<乌鸦传媒>Targeted Drug Yields Durable Responses in Rare Blood Neoplasm Most advanced systemic mastocytosis patients responded to KIT D816V inhibitor Apr 13, 2021
<乌鸦传媒>Another FGFR Inhibitor Active in Bile Duct Cancers Clinical benefit rate of 82% in patients selected for FGFR2 fusions, rearrangements Apr 13, 2021
<乌鸦传媒>Dual Targeted Tx a 'Meaningful' Option in BRAF-Mutant Glioma One-third of glioblastoma patients responded to dabrafenib-trametinib Apr 12, 2021
<乌鸦传媒>A Win for Nivolumab as Preoperative Therapy for Lung Cancer Pathologic CR rate 12 times higher with the addition of anti-PD-1 agent to chemo Apr 11, 2021
<乌鸦传媒>Immunovirotherapy Shows Promise in Pediatric High-Grade Glioma Small study showed responses in 11 of 12 patients Apr 11, 2021
<乌鸦传媒>Nivolumab Alone Prevails in Resected Melanoma Adding ipilimumab in adjuvant setting failed to improve relapse-free survival Apr 11, 2021
<乌鸦传媒>Mixed Results for Immunotherapy in Metastatic Prostate Cancer Combination trial missed response endpoint but exceeded historical results Apr 11, 2021
<乌鸦传媒>Practice-Changing Results in Metastatic Uveal Melanoma Bispecific T cell-engaging tebentafusp reduces survival hazard by 50% Apr 10, 2021
<乌鸦传媒>Add-On PI3K Inhibitor Wins in Relapsed, Indolent NHL Adding copanlisib to rituximab also doubled CR rate, with manageable toxicity Apr 10, 2021
<乌鸦传媒>Worse Blood Cancer Outcomes in Hispanics Diagnosis at earlier age, worse survival, especially for those on U.S.-Mexico border Jun 24, 2020
<乌鸦传媒>6-Week Keytruda Safe, Effective in Melanoma Schedule gets FDA approval for all adult indications Apr 30, 2020
<乌鸦传媒>Talzenna Misses OS Endpoint in BRCA-Positive Breast Cancer But PARP inhibitor improved patient-reported outcomes over standard therapy Apr 29, 2020
<乌鸦传媒>COVID-19 Mortality Spikes in Patients With Lung, Blood Cancers Those with metastatic disease also at special risk for poor outcomes Apr 28, 2020
<乌鸦传媒>Anti-PD-L1 Plus PARP Inhibitor Ups Response in Breast Cancer Add-on treatment superior to chemo alone, but questions remain about cost, toxicity Apr 28, 2020
<乌鸦传媒>Triplet Succeeds in BRAF-Mutant Melanoma Immunotherapy plus BRAF/MEK inhibition boosts PFS over targeted agents alone Apr 27, 2020
<乌鸦传媒>Durable Responses With Keytruda in Later-Line SCLC Plus umbralisib in marginal zone lymphoma and a next-generation TRK-targeted agent Apr 04, 2019
<乌鸦传媒>Genetic Variant Tied to Stroke After Brain Irradiation Tripled stroke risk in survivors of childhood cancers Apr 04, 2019
<乌鸦传媒>Birth Control Pills Tied to Reduced Risk of Deadly Ovarian Ca Every 5 years of use linked with 32% reduction in risk of dying within 12 months of diagnosis Apr 04, 2019
<乌鸦传媒>PARP Inhibitor Maintenance for Pancreatic Cancer Study takes cue from new treatment paradigm in BRCA-mutant ovarian cancer Apr 03, 2019
<乌鸦传媒>Reversing Melanoma Resistance to Immunotherapy HDAC inhibitor/anti-PD-1 combo active after initial anti-PD-1 failure Apr 02, 2019
<乌鸦传媒>Overall Survival Data in for Gilteritinib as AML Salvage Tx FLT3 Inhibitor tops chemotherapy in randomized trial Apr 01, 2019
<乌鸦传媒>MET Inhibitor Rescues Some Targeted Tx Failures in NSCLC Savolitinib promising in patients with MET-based resistance to EGFR inhibition Apr 01, 2019
